Amgen Inc.

- On the Q4 2020 earnings call, Amgen recognized that capital continues to flow into the biopharma sector, indicating an environment of intense competition for capital. - The company emphasized that execution is paramount and that they have a track record of quality and speed in innovation and biosimilar development. - They mentioned maintaining flexibility on operating margin and operating with a commitment to productivity and investing in digitization and automation. - While no explicit plans were disclosed regarding new fundraising through debt or equity in 2021, Amgen indicated that they remain open to internal and external investment opportunities. - The focus is on growing volumes and after-tax cash flows with disciplined capital allocation, especially continuing strong investment in biosimilars. - In summary, no direct announcement of new fundraising was made, but the company maintains financial flexibility to pursue internal growth and external investments.

- Amgen plans to increase R&D investment in 2021 focused on promising mid-stage pipeline candidates. - Capital continues to flow into the biopharma sector, prompting Amgen to maintain strong execution and invest strategically. - The company is investing in digitization and automation to enhance productivity and commercial effectiveness. - Investments are being made to expand promotional footprints for products like Otezla into new patient populations and primary care. - Amgen continues to allocate capital toward its biosimilar franchise, viewing biosimilars as a strong capital allocation area with competitive margins. - External investment opportunities remain a focus, complemented by internal innovation. - Long-term research strategy investments include building capabilities in human genetics, large-scale proteomics, and induced proximity platforms (targeted protein degradation and multi-specific drugs). - Committed to carbon neutrality by 2027 and environmental sustainability initiatives, reflecting strategic ESG investments.

- Expect continued volume growth from key products: Prolia, Otezla, Repatha, EVENITY, and innovative oncology portfolio. - Anticipate ongoing momentum for Repatha globally, driven by international growth and stable US net pricing. - Otezla expected to grow through international launches, mild to moderate psoriasis indication approval, and expanded primary care promotion. - Biosimilars to drive volume growth, though net selling prices may decline due to competition. - Aimovig volumes grew 21% year-over-year despite new patient start challenges; launching internationally to sustain growth. - Q4 product sales grew 8% year-over-year, reflecting strong volume increases. - 2021 revenue guidance: $25.8 billion to $26.6 billion with volume growth offsetting mid-single digit net price declines. - Expect some 2021 revenue and earnings variability due to COVID-19 impacts. - Operating margin targeted at roughly 50% in 2021 with ongoing investments in innovation.

- Amgen expects **2021 non-GAAP earnings per share (EPS) guidance** in the range of **$12.12 to $13.17** per share, reflecting growth over 2020. - **Operating margin** is projected to be around **50%** in 2021, supported by an industry-leading cost structure. - Revenue growth guidance for 2021 is between **$25.8 billion to $26.6 billion**, driven by volume growth in key products like Prolia, Otezla, Repatha, EVENITY, and innovative oncology portfolio. - Non-GAAP operating expenses projected to grow approximately **7%** in 2021, supporting investments in innovation and future launches. - Mid-single digit global **net selling price declines** expected, partly offset by volume growth. - Continued focus on **digitization and automation** to sustain efficient commercial operations and margin expansion. - Amgen aims for sustainable **long-term operating margin improvement**, balancing investment and productivity.

The provided transcript does not mention any details regarding the current or expected orderbook or pending orders. The discussion primarily focuses on: - Product performance and pipeline updates (e.g., sotorasib, tezepelumab). - Regulatory filings and designations. - Commercial strategies and adaptations post-COVID (e.g., digital capabilities, field force adjustments). - Biosimilar competition and market dynamics. - Early stage R&D focus areas and collaborations. - Sales growth figures (e.g., 9% product sales growth, 15% volume growth in 2020). No explicit data or commentary on pending orders or orderbook status is included in the excerpts from pages 1, 3, 6, and 7 of the Q4 2020 earnings call transcript.